Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Ulviprubart in Inclusion Body Myositis (Extension Study)
2024-517623-39-00Phase 3Completed
- Sponsor
- Abcuro
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of ulviprubart in inclusion body myositis (IBM), sponsored by Abcuro. Primary endpoint: Incidence, type, and severity of treatment-emergent adverse events (TEAEs). Started Apr 2025; status: completed.
02
Drugs
ulviprubart
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on 2024-517623-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517623-39-00.